VASCULAR FLOW TECHNOLOGIES

Vascular Flow Technologies launches Spiral Flow™ PV Bypass Graft registry in Germany

Spiral Flow™ Graft implanted in live-case during 
Vascular/Endovascular Masterclass

Dundee, UK, 22 October, 2015 – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow™ (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces the launch of its Spiral Flow™ PV Bypass Graft registry at the 31st annual Deutschen Gesellschaft für Gefäßmedezin (DGG) in Münster.

The multi-centre, observational, post-market registry will collect longitudinal clinical performance outcomes of the Spiral Flow™ Peripheral Bypass Graft in patients undergoing femoro-popliteal bypass (for treatment of severe blockage due to plaque in the femoral artery). The study will be undertaken by GermanVasc, the German vascular society, and will observe the use of Spiral Flow™ Peripheral Bypass Graft in 100 patients with peripheral arterial occlusive disease over a two year period.

Professor Debus, Principal Investigator of the Spiral Flow™ PV Bypass Graft registry and Chair of the European Society of Vascular Surgery commented, “With more than 450,000 patients being treated in Germany annually for vascular disease annually it was important that comprehensive data is collected through a nationwide web-based recording of relevant vascular interventions to facilitate a greater understanding of the role of innovative technology on patient outcomes.”

The implantation of Vascular Flow Technologies’ Spiral Flow™ Graft was successfully demonstrated in a live case during the German Vascular/Endovascular Masterclass held in Hamburg on 9th October. The session specifically showcases new techniques and therapy methods for innovative medical technologies.

Bill Allan, CEO of Vascular Flow Technologies, commented: “The launch of the new Spiral Flow™ PV Bypass Graft registry in Germany is part of ongoing activities to provide long term clinical evidence of Spiral Flow™ Graft performance when used in different clinical settings. This registry complements similar studies underway at over 20 sites across the EU, UK and US.”

Progress of the registry is now well underway, with 12 hospital sites already signed up.